ficusin has been researched along with Cutaneous T-Cell Lymphoma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, T; Masuda, K; Mori, K; Nakahashi, K; Nihira, K; Suzuki, M | 1 |
| Brandozzi, G; Bugatti, L; Campanati, A; Filosa, G; Giacchetti, A; Giantomassi, F; Goteri, G; Molinelli, E; Morsia, E; Mozzicafreddo, G; Offidani, AM; Olivieri, A; Rupoli, S; Serresi, S; Simonacci, M; Torre, E | 1 |
| Heshmati, F | 1 |
| Duvic, M; Morris, L; Reddy, S; Tran, J; Vu, A | 1 |
| Bagot, M; Dreno, B; Dummer, R; Foss, F | 1 |
| Ananthaswamy, HN; Bucana, C; Byrne, S; Matsumura, Y; Nghiem, DX; Ullrich, SE; Walterscheid, JP; Wolf, P | 1 |
| Geskin, L | 1 |
| Almagro, M; del Pozo, J; Fonseca, E; García-Silva, J; Martínez, W; Vázquez, J; Yebra-Pimentel, MT | 1 |
1 review(s) available for ficusin and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
Topics: Ficusin; Humans; Lymphoma, T-Cell, Cutaneous; Photopheresis; Photosensitizing Agents; Skin Neoplasms; Treatment Outcome; Ultraviolet Therapy | 2007 |
7 other study(ies) available for ficusin and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
A novel mouse model of cutaneous T-cell lymphoma revealed the combined effect of mogamulizumab with psoralen and ultraviolet a therapy.
Topics: Animals; Ficusin; Lymphoma, T-Cell, Cutaneous; Methoxsalen; Mice; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Ultraviolet Therapy | 2022 |
Prognosis in early stage cutaneous T-cell lymphoma treated with psoralen plus ultraviolet A irradiation and low-dose interferon-α: Long-term efficacy and survival according to conventional and emerging clinical endpoints.
Topics: Ficusin; Humans; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Neoplasm Recurrence, Local; Prognosis; PUVA Therapy; Skin Neoplasms; Treatment Outcome | 2022 |
[The past, present and future of extracorporeal photopheresis].
Topics: Ficusin; History, 20th Century; History, Ancient; Humans; Immune Tolerance; Immunity, Cellular; Lymphoma, T-Cell, Cutaneous; Photopheresis; Photosensitizing Agents; Sezary Syndrome; Skin Neoplasms; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory | 2020 |
Anaphylaxis following administration of extracorporeal photopheresis for cutaneous T cell lymphoma.
Topics: Adult; Anaphylaxis; Anticoagulants; Disinfectants; Ethylene Oxide; Female; Ficusin; Glucocorticoids; Heparin; Histamine Antagonists; Humans; Lymphoma, T-Cell, Cutaneous; Photopheresis; Photosensitizing Agents; Skin Neoplasms | 2020 |
Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Topics: Aged; Antineoplastic Agents; Carmustine; Combined Modality Therapy; Dermatitis, Exfoliative; Erythema Nodosum; Female; Ficusin; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Phototherapy; PUVA Therapy; Sezary Syndrome; Skin Neoplasms | 2006 |
Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis.
Topics: Animals; Apoptosis; Candida albicans; Candidiasis; Combined Modality Therapy; Female; Ficusin; Humans; Hypersensitivity, Delayed; Immune Tolerance; Immunosuppression Therapy; Inflammation; Interleukin-10; Lymphoma, T-Cell, Cutaneous; Male; Mice; Mice, Knockout; Platelet Activating Factor; Platelet Membrane Glycoproteins; Psoriasis; PUVA Therapy; Receptors, G-Protein-Coupled; Signal Transduction | 2006 |
Cutaneous T-cell lymphoma presenting as disseminated, pigmented, purpura-like eruption.
Topics: Ficusin; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; PUVA Therapy; Skin; Skin Neoplasms | 2001 |